Medeiros, Bruno C.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,250

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014) · Proceedings of the National Academy of Sciences

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 705

Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia

Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports

Acute Myeloid Leukemia ResearchCytokine Signaling Pathways and Interactions

Cited by 270

Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML

Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 164